View Post

Trodelvy: Magic bullet for triple-negative breast cancer

In In The News by Barbara Jacoby

By: Ivanhoe Newswire From: winknews.com About 15 percent of all women diagnosed with breast cancer have triple-negative breast cancer, meaning drugs that target estrogen, progesterone, and HER-2 protein—won’t work. In the past, if the cancer returned, patients have had very few options. More on a newly approved drug that is stopping the cancer in its tracks. Jane Ellen Keenan is …

View Post

Rare Patient Voice: Acute Myeloid Leukemia Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 90 min Web-Assisted Phone Interview Compensation $200 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Surgery Boosts Survival in De Novo Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021. BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer …

View Post

Amazon Care and privacy: A host of unknowns

In In The News by Barbara Jacoby

By: Matt Fisher From: medcitynews.com If HIPAA does not apply to Amazon Care, then absent another privacy regulation applying, avoiding exploitation of the data relies on the good faith of the entity operating the service. The recent announcement by Amazon concerning a national launch of its telehealth offering, Amazon Care, is generating a significant amount of buzz and speculation within …

View Post

Rare Patient Voice: Diffuse large B-cell lymphoma Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 150 min Online Bulletin Board Compensation $150 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others with …

View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Better Record “Integration” Would Boost Links Between Oncologists, Primary Care

In In The News by Barbara Jacoby

By: Mary Caffrey From: ajmc.com A panel at the NCCN Virtual Annual Meeting finds that while primary care physicians and oncologists can share information, records may not be well integrated and in easy-to-use formats. When connections among oncologists, cancer patients, and primary care physicians are finely tuned, the results can be life-saving for patients like Felicia Harris, a 14-year breast …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …

View Post

Predicting future breast cancer with precision

In In The News by Barbara Jacoby

By: Alex Lathbridge From: cancerresearchuk.org Ductal carcinoma in situ (or DCIS) is a condition where some of the cells lining the ducts of the breast tissue have started to turn into cancer cells. It’s an example of something known as a pre-invasive cancer – the abnormal cells are all contained inside the lining of the ducts, but have the potential …

View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …